SCHEMBL7033706

SCHEMBL7033706

NNc1cnc2ccccc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.62
KDR P35968 1/20 0.54
KDM4E B2RXH2 8/20 0.53
CYP1A2 P05177 1/20 0.52
RAB9A P51151 10/20 0.51
NPC1 O15118 9/20 0.51
SMN1; SMN2 Q16637 7/20 0.51
ALDH1A1 P00352 6/20 0.51
LMNA P02545 4/20 0.51
HTT P42858 3/20 0.51
HPGD P15428 2/20 0.51
GFER P55789 1/20 0.51
MAPT P10636 3/20 0.50
POLB P06746 2/20 0.50
HSD17B10 Q99714 2/20 0.49
TSHR P16473 1/20 0.49
MITF O75030 1/20 0.49
XBP1 P17861 1/20 0.49
PAX8 Q06710 1/20 0.49
KLF5 Q13887 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2081815 0.98 NPSR1 (0.60) NPSR1KDRKDM4ECYP1A2RAB9A
Hydrochloric Acid SCHEMBL8606417 0.98 NPSR1 (0.60) NPSR1KDRKDM4ECYP1A2RAB9A
Hydrochloric Acid SCHEMBL25250658 0.98 NPSR1 (0.60) NPSR1KDRKDM4ECYP1A2RAB9A
SCHEMBL30824513 0.80 NPSR1 (0.57) NPSR1KDRKDM4ECYP1A2RAB9A
SCHEMBL128095 0.80 NPSR1 (0.57) NPSR1KDRKDM4ECYP1A2RAB9A
SCHEMBL28007469 0.80 NPSR1 (0.57) NPSR1KDRKDM4ECYP1A2RAB9A
SCHEMBL11591503 0.80 NPSR1 (0.57) NPSR1KDRKDM4ECYP1A2RAB9A
SCHEMBL23055256 0.80 NPSR1 (0.57) NPSR1KDRKDM4ECYP1A2RAB9A
SCHEMBL11591505 0.80 NPSR1 (0.57) NPSR1KDRKDM4ECYP1A2RAB9A
SCHEMBL2111139 0.78 KDM4E (0.58) NPSR1KDRKDM4ECYP1A2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118109824-A Carbon dioxide corrosion inhibitor based on Mannich base and preparation method and application thereof 中国石油天然气集团有限公司 2024-05-31 CN claimed
CN-103626767-A Azaindole with regionselectivity and synthetic method thereof WUXI APPTEC CO LTD 2014-03-12 CN claimed
US-6440896-B1 FIRST DEVELOPER SOLUTION AND DISTINCT SECOND DEVELOPER SOLUTION PRODUCE DIFFERENT COLORS; COLOR STABILITY, WEAR RESISTANCE; INCORPORATING WITHIN A PROTECTIVE MEDIUM EASTMAN KODAK COMPANY 2002-08-27 US claimed
US-6197722-B1 STORAGE STABILITY; IMAGES HAVING COLOR SATURATION AND COLOR GAMUT; INK JET PRINTING; NONSMEARING EASTMAN KODAK COMPANY 2001-03-06 US claimed
US-6143693-A STORAGE STABILITY; ENABLES TO PRODUCE IMAGES HAVING COLOR SATURATION AND COLOR GAMUT, RESISTANCE TO DARK AND LIGHT FADE, RESISTANCE TO IMAGE SMEAR AND RUB-OFF, MOISTURE AND HUMIDITY RESISTANCE EASTMAN KODAK COMPANY (US) 2000-11-07 US claimed
CN-118109824-A Carbon dioxide corrosion inhibitor based on Mannich base and preparation method and application thereof 中国石油天然气集团有限公司 2024-05-31 CN disclosed
CN-118109824-A Carbon dioxide corrosion inhibitor based on Mannich base and preparation method and application thereof 中国石油天然气集团有限公司 2024-05-31 CN disclosed
CN-114540846-B Synthesis method of 1,2, 4-triazolo six-membered nitrogen heterocycle-3-amine 五邑大学 2023-09-19 CN disclosed
CN-114540846-A Synthetic method of 1,2, 4-triazolo hexa-nitrogen heterocyclic-3-amine 五邑大学 2022-05-27 CN disclosed
US-11306096-B2 4,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancer MISSION THERAPEUTICS LIMITED (GB) 2022-04-19 US disclosed
EP-3430012-B1 4,6-DIHYDROPYRROLO[3,4-C]PYRAZOLE-5(1H)-CARBONITRILE DERIVATIVES FOR TREATING CANCER MISSION THERAPEUTICS LTD (GB) 2021-06-16 EP disclosed
CN-103626767-A Azaindole with regionselectivity and synthetic method thereof WUXI APPTEC CO LTD 2014-03-12 CN disclosed
US-4975512-A Crosslinking with amine, ammonium, hydrazine PETROLEUM ENERGY CENTER (JP) 1990-12-04 US disclosed
US-4970210-A ENZYME INHIBITORS ABBOTT LABORATORIES (US) 1990-11-13 US disclosed
EP-0304239-A1 Reformed polysilazane and method of producing same TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) 1989-02-22 EP disclosed
EP-0299449-A2 Pyridazinone, triazinone and oxapyridazinone lipoxygenase inhibiting compounds ABBOTT LABORATORIES (US) 1989-01-18 EP disclosed
EP-0055418-B1 PYRAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM THE WELLCOME FOUNDATION LIMITED (GB) 1986-02-26 EP disclosed
US-4524146-A NERVOUS SYSTEM DISORDERS CIBA-GEIGY CORPORATION (US) 1985-06-18 US disclosed
EP-0055418-A2 Pyrazoline derivatives, processes for their preparation and pharmaceutical formulations containing them THE WELLCOME FOUNDATION LIMITED (GB) 1982-07-07 EP disclosed
US-4094683-A HETEROCYCLIC QUATERNARY AMMONIUM COMPOUND AS FOGGING AGENT FUJI PHOTO FILM CO., LTD. (JA) 1978-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11306096-B2 4,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancer USP7, USP1, USP3 NPSR1 3538/4885KDR 4672/4885KDM4E 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.